This page shows the latest iniparib news and features for those working in and with pharma, biotech and healthcare.
Sanofi was forced to abandon development of its iniparib candidate, which had been in trials for breast and non-small cell lung cancer (NSCLC).
AbbVie now has now closed the gap in the race to bring the first PARP inhibitor to market, particularly with the demise of Sanofi's former leader iniparib last year.
Moreover, the late-stage failure last year of another PARP inhibitor - Sanofi's iniparib - because of a lack of efficacy may have encouraged caution on the behalf of the panellists.
Some companies have struggled in the area, however, including Sanofi, which saw its investigational drug iniparib fail to meet trial targets in 2011.
PARP inhibitors are designed to treat cancer by blocking the repair of DNA in tumour cells, although some of the early drug candidates - notably Sanofi's iniparib - ran into hurdles and
The recent demise of Sanofi's rival candidate iniparib after a phase III trial failure means that AZ is among the leaders in the PARP inhibitor field, although several other drugs
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...